Condition
DS Stage II Multiple Myeloma
Total Trials
3
Recruiting
0
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
0%
3 of 0 completed with results
Key Signals
3 with results
Data Visualizations
Phase Distribution
3Total
P 3 (3)
Trial Status
Active Not Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT00114101Phase 3Active Not Recruiting
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
NCT00644228Phase 3Active Not Recruiting
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT00098475Phase 3Active Not Recruiting
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma
Showing all 3 trials